Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular biomarkers in clinical studies of type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  1. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  4. Evaluation of clinical translatability of the diet-induced obese and biopsy-confirmed gubra amylin mouse model of non-alcoholic steatohepatitis

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The duodenal-jejunal bypass sleeve ((DJBS) or EndoBarrier Gastrointestinal Liner) induces weight loss in obese subjects and may improve glucose homeostasis in patients with type 2 diabetes (T2D). To explore the underlying mechanisms, we evaluated postprandial physiology including glucose metabolism, gut hormone secretion, gallbladder emptying, appetite and food intake in patients undergoing DJBS treatment.

MATERIAL AND METHODS: A total of 10 normal glucose-tolerant (NGT) obese subjects and 9 age-, body weight- and body mass index-matched metformin-treated T2D patients underwent a liquid mixed meal test and a subsequent ad libitum meal test before implantation with DJBS and 1 week (1w) and 26 weeks (26w) after implantation.

RESULTS: At 26w, both groups had achieved a weight loss of 6 to 7 kg. Postprandial glucagon-like peptide-1 (GLP-1) and peptide YY responses increased at 1w and 26w, but only in T2D subjects. In contrast, glucose-dependent insulinotropic polypeptide responses were reduced only by DJBS in the NGT group. Postprandial glucose, insulin, C-peptide, glucagon, cholecystokinin and gastrin responses were unaffected by DJBS in both groups. Satiety and fullness sensations were stronger and food intake was reduced at 1w in NGT subjects; no changes in appetite measures or food intake were observed in the T2D group. No effect of DJBS on postprandial gallbladder emptying was observed, and gastric emptying was not delayed.

CONCLUSIONS: DJBS-induced weight loss was associated with only marginal changes in postprandial physiology, which may explain the absence of effect on postprandial glucose metabolism.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number2
Pages (from-to)189-99
ISSN1462-8902
DOIs
Publication statusPublished - 2017

ID: 49288148